Table 7.
Trials evaluating halogenated pyrimidines as radiosensitizers, sorted by publication year
| Author | Year | Agent | Dose | n | Radiation regimen | Results |
|---|---|---|---|---|---|---|
| Jackson et al. [42] | 1987 | BUdR | 650 mg/m2/day as 12 h or 24 h-iv, 2 × 14 days | 60 (50) | 65–70 Gy in 35 fractions (BUdR) |
Median OS: 13 months IUdR vs BUdR: no survival difference |
| IUdR | 1000 mg/m2/day as 12 h or 24 h-iv, 2 × 14 days | 45 Gy in 30 fractions bid +25 Gy Boost in 20 fractions bid (IUdR) | ||||
| Matsutani et al. [43] | 1988 | BUdR | 800–1000 mg/m2/day for 5 days a week | 23 (7) | 50–60 Gy in 25–30 fractions | Median TTP (GBM): 37 weeks |
| Greenberg et al. [44] | 1988 | BUdR | 400 mg/m2/day as 24 h-iv for 8 weeks | 18 (15) | 59.4 Gy in 33 fractions | Median OS: 22 months |
| Hegarty et al. [45] | 1990 | BUdR | 400–600 mg/m2/day as 24 h-iv, 8.5 weeks | 23 (18) | 59.4 Gy in 33 fractions | Median OS: 20 months |
|
Phillips et al. [51] |
1991 | BUdR | 800 mg/m2/day as 24 h-iv for 4 days a week | 160 | 60 Gy in 30 fractions |
Median OS: 55.7 weeks Median TTP: 34.5 weeks |
| Goffman et al. [48] | 1992 | IUdR | 1000 mg/m2/day as 12 h or 24 h-iv, 2 × 14 days | 45 | 45 Gy in 30 fractions bid +25–30 Gy boost in 20 fractions bid |
No significant benefit of IUdR Median OS: 11 months |
|
Vokes et al. [50] |
1993 | IUdR | 125–500 mg/m2/day as 24 h-iv, 2 × 5 days | 15 (11) | 65 Gy in 36 fractions | Significant systemic toxicity when combined with 5‑FU and HU |
| + 5-FU | 300 mg/m2/day, 5 days | |||||
| + Hydroxyurea | 500 mg tid, 11 doses | |||||
| Urtasun et al. [47] | 1993 | IUdR | 1000 mg/m2/day as 24 h-iv, 48 h-iv or 96 h-iv | 79 (56) | 60.16 Gy in 32 fractions | Median OS: 13.4 months for 96 h-iv (vs 10.5 months for 48 h-iv vs 11 months for 24 h-iv) |
| Greenberg et al. [46] | 1994 | BUdR | 400 mg/m2/day 24 h-iv | 62 (58) | 59.4 Gy in 33 fractions |
Median OS: 18 months Co-delivery with 5‑FU tolerable |
| + 5-FU |
5 mg/m2/day iv for 8.5 weeks |
|||||
|
Groves et al. [49] |
1999 | BUdR |
2.1 g/m2/day as 24 h-iv, 2 × 4 days |
88 |
55.5–57 Gy in 30 fractions tid, one week on, one week off |
Median OS: 50 weeks, Median TTP: 28.5 weeks High derma- and hematological toxicity |
n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)